Use of amantadine in Parkinson's disease. Results of a double-blind trial.
In a four-week double-blind trial of 62 patients with Parkinsonism 29 were treated withamantadine and 33 with a placebo. Modest but statistically significant improvement was observed in the first group, optimum benefit occurring after the first two weeks. Patients' reactions to the drug were favourable in 79%, and side effects were insignificant. Though amantadine appears to be a useful additive drug in the treatment of Parkinsonism, its value as a single treatment is as yet undetermined.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos; D013035:Spasm / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy
D010919:Placebos; D000547:Amantadine